Drug intelligence / Profile preview

HPP2104-2

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules

Overview

HPP2104-2 is an investigational drug referenced in clinical trials for essential hypertension. It was studied as part of a multicenter, randomized, double-blind, phase III trial conducted by Hanmi Pharmaceutical Company Limited. The trial evaluated the efficacy and safety of HCP2102 (a related or possibly identical compound; note that "HCP" and "HPP" may be typographical or coding variations) in patients with essential hypertension. The specific mechanism of action, chemical structure, and detailed pharmacological profile for HPP2104-2 are not publicly disclosed in available sources[4][10].

Beyond the preview

Go deeper on HPP2104-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPP2104-2.

Explore the full profile